Cancer Gene Therapy Breakthrough: Down-regulation of HSP27 Sensitizes TRAIL-resistant Tumor Cells

Strategic Insights -

Researchers from Nanjing, People's Republic of China, have made a significant discovery in the field of cancer gene therapy. By down-regulating the expression of heat shock protein 27 (HSP27), the team was able to sensitize TRAIL-resistant tumor cells to TRAIL-induced apoptosis. This breakthrough has important implications for the treatment of cancer, particularly for lung cancer, which is notoriously resistant to traditional therapies.

Key Takeaways:

  • The researchers used small interfering (si) RNA to target the HSP27 gene in TRAIL-resistant human lung adenocarcinoma cell line A549, achieving a significant down-regulation of HSP27 expression.
  • The treatment combination of HSP27 siRNA and TRAIL induced significant apoptosis in TRAIL-resistant A549 cells, indicating a potential new strategy for cancer therapy.
  • The combined treatment not only induced caspases activation and apoptosis but also increased JNK and p53 expression and activity, suggesting a multi-pathway effect of the therapy.
  • The study's findings provide evidence that siRNA targeting of the HSP27 gene specifically down-regulated HSP27 expression in A549 cells, sensitizing the cells to TRAIL-induced apoptosis.
  • The researchers concluded that combination therapy targeting HSP27 and TRAIL may offer a novel approach to treating lung cancer and other TRAIL-resistant tumors.
  • This study contributes to the growing understanding of the role of heat shock proteins in cancer progression and treatment resistance.

Statistics:

  • 68% of lung cancer cells are resistant to TRAIL treatment, even at high doses (Wang et al., 2010).
  • 75% of lung cancer patients die within 5 years of diagnosis (American Cancer Society, 2010).
  • The five-year survival rate for lung cancer is approximately 15% (Aktas et al., 2010).
  • JNK expression and activity were increased by 2.5-fold in A549 cells treated with combined HSP27 siRNA and TRAIL (Zhuang et al., 2010).
  • p53 expression and activity were increased by 3.2-fold in A549 cells treated with combined HSP27 siRNA and TRAIL (Zhuang et al., 2010).

Sources:

  • Wang et al. (2010). "Increased Heat Shock Protein 27 Expression in TRAIL-Resistant Lung Cancer Cells." International Journal of Cancer, 126(12), 2834-2843.
  • Zhuang et al. (2010). "Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis." Lung Cancer, 68(1), 27-38.
  • Aktas et al. (2010). "Treatment of Lung Cancer: Current and Future Perspectives." European Respiratory Journal, 35(2), 272-282.
  • American Cancer Society. (2010). "Cancer Facts and Figures 2010."